Join the Paliperidone group to help and get support from people like you.
Paliperidone News
Related terms: Paliperidone Palmitate
FDA Approves Erzofri (paliperidone palmitate) for the Treatment of Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., July 28, 2024 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that ...
FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
FDA Medwatch Alert: Paliperidone Extended-Release Tablets 3mg by Teva Pharmaceuticals: Recall - Dissolution Test Failure
ISSUE: Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles, lot 1160682A,...
FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia
TITUSVILLE, N.J., May 19, 2015 – There’s a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered j...
FDA Approves sNDA for Invega Sustenna (paliperidone palmitate) for Schizoaffective Disorder
TITUSVILLE, N.J., Nov. 13, 2014 /PRNewswire/ – Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Applications (sNDAs)...
Further information
Related condition support groups
Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Autism, Borderline Personality Disorder, Depression